P53 autoantibodies in 1006 patients followed up for breast cancer

被引：34

作者：

Metcalfe S. ^{[1
]}

Wheeler T.K. ^{[1
]}

Picken S. ^{[1
]}

Negus S. ^{[1
]}

Milner A.J. ^{[2
]}

机构：

[1] Addenbrookes Hospital, Cambridge

[2] Yorkshire Cancer Research p53 Lab., University of York, York

来源：

Breast Cancer Research | / 2卷 / 6期

关键词：

Breast; Cancer; Monitoring; P53; autoantibodies;

D O I：

10.1186/bcr91

中图分类号：

学科分类号：

摘要：

Serial plasma samples from 1006 patients with breast cancer revealed: (i) no correlation of p53 autoantibody status with disease status at the time of sample collection, or with menopausal status at time of primary diagnosis of breast cancer; (ii) 155 out of 1006 (15%) of patients were positive for p53 autoantibodies, and these patients tended to have a persistent autoantibody status throughout follow up, irrespective of disease behaviour; and (iii) where a negative autoantibody status was found at primary diagnosis of breast cancer, this negative status persisted throughout follow up, irrespective of later disease behaviour. We conclude that screening for p53 autoantibody status is not informative on residual tumour activity nor on therapeutic responsiveness.

引用

页码：438 / 443

页数：5

共 17 条

[1]

Silvestrini R., Diadone M.G., Benini E., Faranda A., Tomasic G., Boracchi P., Validation of p53 accumulation as a predictor of distant metastases at 10 years of followup in 1400 node-negative breast cancers, Clin Cancer Res, 2, pp. 2007-2013, (1996)

[2]

Crawford L., Pim D.C., Bulbrook R.D., Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer, Int J Cancer, 30, pp. 403-408, (1982)

[3]

Lubin R., Schlichtholz B., Teillaud J.L., Garay E., Bussel A., Wild C.P., P53 antibodies in patients with various types of cancer: Assay, identification, and characterisation, Clin Cancer Res, 1, pp. 1463-1469, (1995)

[4]

Peyrat J.P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., Soussi T., Prognostic significance of circulating p53 antibodies in patients undergoing surgery for loco-regional breast cancer, Lancet, 345, pp. 621-622, (1995)

[5]

Lenner P., Wiklund F., Emdin S.O., Arnerlov C., Eklund C., Hallmans G., Zentgraf H., Dillner J., Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer, Br J Cancer, 79, pp. 927-932, (1999)

[6]

Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T., The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot, Cancer Res, 52, pp. 6380-6384, (1992)

[7]

Mudenda B., Green J.A., Green B., Jenkins J.R., Robertson L., Tarunina M., Leinster S.J., The relationship between serum p53 autoantibodies and characteristics of human breast cancer, Br J Cancer, 69, pp. 1115-1119, (1994)

[8]

Dalifard I., Daver A., Larra F., Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors, Anticancer Res, 19, pp. 5015-5022, (1999)

[9]

Zalcman G., Schlichtholz B., Tredaniel J., Urban T., Lubin R., Dubois I., Milleron B., Hirsch A., Soussi T., Monitoring p53 autoantibodies in lung cancer during therapy: Relationship to response to treatment, Clin Cancer Res, 4, pp. 1359-1366, (1998)

[10]

Bergqvist M., Brattstrom D., Larsson A., Holmertz J., Hesselius P., Rosenberg L., Wagenius G., Brodin O., P53 autoantibodies in none-small cell lung cancer patients can predict increased life expectancy after radiotherapy, Anticancer Res, 18, pp. 1999-2002, (1998)

← 1 2 →